Your browser is no longer supported. Please, upgrade your browser.
Processa Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own22.50% Shs Outstand5.59M Perf Week2.73%
Market Cap118.83M Forward P/E- EPS next Y-0.60 Insider Trans0.05% Shs Float4.33M Perf Month86.09%
Income-6.00M PEG- EPS next Q-0.37 Inst Own17.90% Short Float0.28% Perf Quarter89.61%
Sales- P/S- EPS this Y0.90% Inst Trans- Short Ratio0.21 Perf Half Y47.01%
Book/sh0.99 P/B12.16 EPS next Y54.90% ROA-58.90% Target Price13.50 Perf Year-56.46%
Cash/sh0.03 P/C396.12 EPS next 5Y- ROE-87.10% 52W Range3.40 - 13.35 Perf YTD82.56%
Dividend- P/FCF- EPS past 5Y29.80% ROI- 52W High-9.81% Beta0.15
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low254.12% ATR1.22
Employees13 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)65.44 Volatility12.96% 14.41%
OptionableNo Debt/Eq0.31 EPS Q/Q-252.40% Profit Margin- Rel Volume1.02 Prev Close12.83
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume58.50K Price12.04
Recom2.00 SMA2028.61% SMA5051.98% SMA20034.31% Volume59,568 Change-6.16%
Mar-02-21 09:15AM  
Feb-22-21 08:30AM  
Feb-19-21 05:16AM  
Feb-17-21 08:00AM  
Jan-11-21 10:50AM  
Nov-16-20 12:48PM  
Nov-12-20 05:02PM  
Nov-05-20 09:15AM  
Nov-03-20 09:20AM  
Oct-13-20 09:30AM  
Oct-07-20 09:25AM  
Oct-06-20 04:05PM  
Oct-02-20 06:00AM  
Aug-27-20 09:30AM  
Aug-20-20 09:30AM  
Jun-01-20 09:30AM  
Mar-30-20 04:00PM  
Mar-17-20 09:30AM  
Mar-05-20 09:30AM  
Feb-25-20 09:30AM  
Feb-13-20 09:30AM  
Dec-20-19 04:10PM  
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BESSER JAMES E10% OwnerFeb 22Sale11.5620,929241,9391,096,071Feb 22 08:13 PM
BESSER JAMES E10% OwnerFeb 19Sale11.203,00033,6001,117,000Feb 22 08:13 PM
BESSER JAMES E10% OwnerFeb 18Sale11.355,00056,7501,120,000Feb 22 08:13 PM
BESSER JAMES E10% OwnerOct 02Buy4.0430,000121,200405,000Oct 13 06:33 PM